WEBSITECHANGES

Website Changes

---

07/22/2024

Update from our friends at Roon!

---

07/22/2024

Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: a novel combinatorial immunotherapy regimen for gliomas

---

07/15/2024

Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022

---

07/15/2024

Musella Foundation Is Now Accepting Cryptocurrency Donations

---

07/12/2024

Expanded Access Program for gallium maltolate (GaM) Now Open

---

07/08/2024

Musella Foundation Copay Assistance Program is now open!

---

07/01/2024

Application of Delta T1 maps for quantitative and objective assessment of extent of resection and survival prediction in glioblastoma

---

07/01/2024

No benefit from TMZ treatment in GB with truly unmethylated MGMT promotor: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly GB

---

07/01/2024

Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma

---

07/01/2024

Musella Foundation Awards Research Grant

---

06/23/2024

FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park

---

06/13/2024

Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting

---

06/12/2024

Musella Foundation Earns a Four-Star Rating From Charity Navigator

---

06/03/2024

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

---

06/03/2024

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

---

06/03/2024

Brain Cancer Support and Solutions Alliance Launched to Improve Care and Outcomes for Brain Tumor Patients

---

06/03/2024

For Love & Life: No Ordinary Campaign

---

05/28/2024

Introducing Promising Pathway 2.0

---

05/28/2024

Musella Foundation Awards 3 Research Grants!

---

05/28/2024

Brain Tumor Awareness Month Webinar Series

---

05/27/2024

Can Boosting Hydrogen Sulfide Bolster Standard-of-Care Glioblastoma Therapy to Extend Survival?

---

05/27/2024

Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients

---

05/23/2024

IMVAX Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing

---

05/23/2024

President Lech Walesa of Poland Announces Plan to Harness Wind and Solar Energy to Discover Cancer Treatments and Cures

---

05/21/2024

URGENT - Promising Pathway 2.0!

---